Equity
Additional Paid-In Capital
Alnylam Pharmaceuticals Additional Paid-In Capital increased by 1.1% to $7.60B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.3%, from $7.50B to $7.60B. Over 5 years (FY 2020 to FY 2025), Additional Paid-In Capital shows an upward trend with a 5.9% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ3 2015
Last reportedQ4 2025
How to read this metric
An increase typically signals recent equity financing activities or the issuance of shares for employee compensation.
Detailed definition
Additional paid-in capital represents the amount of capital received from investors in excess of the par value of the is...
Peer comparison
Common in all corporations; levels depend on the history of equity issuance and stock-based compensation.
Metric ID:
additional_paid_in_capitalHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.86B | $5.97B | $6.06B | $6.12B | $6.17B | $6.34B | $6.45B | $6.52B | $6.65B | $6.74B | $6.81B | $6.88B | $7.12B | $7.26B | $7.39B | $7.50B | $7.69B | $7.41B | $7.51B | $7.60B |
| QoQ Change | — | +1.8% | +1.5% | +1.0% | +0.9% | +2.7% | +1.9% | +1.0% | +1.9% | +1.4% | +1.1% | +1.0% | +3.5% | +1.9% | +1.8% | +1.5% | +2.6% | -3.6% | +1.3% | +1.1% |
| YoY Change | — | — | — | — | +5.3% | +6.2% | +6.5% | +6.6% | +7.7% | +6.3% | +5.5% | +5.5% | +7.2% | +7.8% | +8.5% | +8.9% | +8.0% | +2.1% | +1.7% | +1.3% |
Range$5.86B – $7.69B
CAGR+5.6%
Avg YoY Growth+5.9%
Median YoY Growth+6.4%
Current Streak2 quarters growth
Additional Paid-In Capital at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's additional paid-in capital?
- Alnylam Pharmaceuticals (ALNY) reported additional paid-in capital of $7.60B in Q1 2026.
- How has Alnylam Pharmaceuticals's additional paid-in capital changed year-over-year?
- Alnylam Pharmaceuticals's additional paid-in capital increased by 1.3% year-over-year, from $7.50B to $7.60B.
- What is the long-term trend for Alnylam Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's additional paid-in capital has grown at a 5.9% compound annual growth rate (CAGR), from $5.64B to $7.51B.
- What does additional paid-in capital mean?
- Capital contributed by shareholders above the nominal par value of the stock.